Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Asuka Okada"'
Autor:
Naoya Nishioka, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Taiki Masui, Natsuki Sai, Masaki Ishida, Yuki Katayama, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionSeveral studies explored the association between thyroid transcription factor-1 (TTF-1) and the therapeutic efficacy of immunotherapy. However, the effect of TTF-1 on the therapeutic efficacy of programmed death-1 (PD-1) inhibitor/chemoim
Externí odkaz:
https://doaj.org/article/b283d63fa0724718827e2777a8b09bb4
Autor:
Yuki Katayama, MD, PhD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, PhD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100644- (2024)
Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitor
Externí odkaz:
https://doaj.org/article/3964141379334812bbe15faf7291e902
Autor:
Shota Takei, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Taishi Harada, Koji Date, Yusuke Chihara, Isao Hasegawa, Nobuyo Tamiya, Yuki Katayama, Naoya Nishioka, Kenji Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Takashi Kijima, Koichi Takayama
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionThe proportion of older patients diagnosed with advanced-stage non-small cell lung cancer (NSCLC) has been increasing. Immune checkpoint inhibitor (ICI) monotherapy (MONO) and combination therapy of ICI and chemotherapy (COMBO) are standa
Externí odkaz:
https://doaj.org/article/0523905fe5d04548b83c0aeba67c60f5
Autor:
Yuki Katayama, MD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Akihiro Yoshimura, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100494- (2023)
Introduction: Lung adenocarcinoma with negative TTF-1 expression is believed to be a poor prognostic factor for certain systemic treatments. Nevertheless, the impact of TTF-1 expression on combined chemoimmunotherapy remains unclear. We aimed to inve
Externí odkaz:
https://doaj.org/article/f5a29b79c158468da31bfa4f00a93ada
Autor:
Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma
Externí odkaz:
https://doaj.org/article/67a827674fcd4c4087dafceff77375be
Autor:
Hayato Kawachi, MD, Motohiro Tamiya, MD, Yoshihiko Taniguchi, MD, Toshihide Yokoyama, MD, Shinya Yokoe, MD, Yuko Oya, MD, PhD, Mihoko Imaji, MD, Fukuko Okabe, MD, Masaki Kanazu, MD, Yoshihiko Sakata, MD, Shinya Uematsu, MD, Satoshi Tanaka, MD, Daisuke Arai, MD, PhD, Go Saito, MD, Hiroshi Kobe, MD, Eisaku Miyauchi, MD, PhD, Asuka Okada, MD, PhD, Satoshi Hara, MD, Toru Kumagai, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100355- (2022)
Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is currently the standard therapy for
Externí odkaz:
https://doaj.org/article/a1964b63c30847029c4b83600c97ce97
Autor:
Tatsuhiro Furuyama, Masahide Ueda, Asuka Okada, Sae Hato, Yuma Watabe, Yusuke Inui, Takahiro Ibaraki, Fumitaka Mito, Hideaki Takenaka, Sumito Choh
Publikováno v:
Haigan. 62:1048-1055
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::163f4475c4de57aaef28830763a5d8e2
https://doi.org/10.2482/haigan.62.1048
https://doi.org/10.2482/haigan.62.1048
Autor:
Takayuki Takeda, Tadaaki Yamada, Keiko Tanimura, Takayuki Nakano, Masaki Ishida, Yusuke Tachibana, Shinsuke Shiotsu, Shigeto Horiuchi, Makoto Hibino, Asuka Okada, Yusuke Chihara, Koichi Takayama
Publikováno v:
Diagnostics, Vol 11, Iss 12, p 2170 (2021)
The prognoses of patients with non-small-cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangement have dramatically improved with the use of ALK tyrosine kinase inhibitors. Although immunological and nutritional markers
Externí odkaz:
https://doaj.org/article/5e054f4d159a475d9d7c4eab41a9ee93
Autor:
Makoto, Hibino, Kiyoaki, Uryu, Takayuki, Takeda, Yusuke, Kunimatsu, Shinsuke, Shiotsu, Junji, Uchino, Soichi, Hirai, Tadaaki, Yamada, Asuka, Okada, Yoshikazu, Hasegawa, Osamu, Hiranuma, Yusuke, Chihara, Riko, Kamada, Shunichi, Tobe, Kazunari, Maeda, Shigeto, Horiuchi, Tetsuri, Kondo, Koichi, Takayama
Publikováno v:
Journal of Thoracic Oncology. 17:1002-1013
Patients with cancer have been prioritized for vaccination against severe acute respiratory syndrome coronavirus 2. Nevertheless, there are limited data regarding the safety, efficacy, and risk of developing immune-related adverse events (irAEs) asso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212b776c9279a0d36946d9ddc005f3a1
https://doi.org/10.1016/j.jtho.2022.05.015
https://doi.org/10.1016/j.jtho.2022.05.015
Autor:
Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Hiroyuki Fujii, Satomi Morita, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Takahiro Yamada, Takahiro Ota, Taishi Harada, Isao Hasegawa, Akihiro Yoshimura, Masahiro Iwasaku, Shinsaku Tokuda, Young Hak Kim, Koichi Takayama
Publikováno v:
JTO Clin Res Rep
INTRODUCTION: Lung adenocarcinoma with negative TTF-1 expression is believed to be a poor prognostic factor for certain systemic treatments. Nevertheless, the impact of TTF-1 expression on combined chemoimmunotherapy remains unclear. We aimed to inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70961ad4f5f2237a61aa79e4b6981a15
https://europepmc.org/articles/PMC10067944/
https://europepmc.org/articles/PMC10067944/
